ALLMedicine™ Alpha-mannosidosis Center
Research & Reviews 37 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308362
Orphanet Journal of Rare Diseases; Hennermann JB, Raebel EM et. al.
Jul 24th, 2022 - Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder (LSD) caused by reduced activity of alpha-mannosidase. Clinical manifestations include skeletal dysmorphism, mental impairment, hearing loss and recurrent infections. The ...
https://clinicaltrials.gov/ct2/show/NCT03651245
Jun 13th, 2022 - Alpha-Mannosidosis is a lysosomal storage disorder of the Glycoprotein family of diseases and is closely related to Mucopolysaccharidoses.It is a rare inherited disorder that causes problems in many organs and tissues of the body. Affected individ...
https://clinicaltrials.gov/ct2/show/NCT02998879
Oct 26th, 2021 - The Primary endpoints of the study include: Safety and tolerability of velmanase alfa as per Adverse events (AEs, including IRR), vital signs, laboratory parameters (hematology, biochemistry and urinanalysis) Detection of anti-velmanase alfa antib...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494324
PloS One; Mkaouar R, Riahi Z et. al.
Oct 7th, 2021 - Alpha-Mannosidosis (AM) is an ultra-rare storage disorder caused by a deficiency of lysosomal alpha-mannosidase encoded by the MAN2B1 gene. Clinical presentation of AM includes mental retardation, recurrent infections, hearing loss, dysmorphic fea...
https://doi.org/10.1017/cjn.2021.208
The Canadian Journal of Neurological Sciences. Le Journal... Malaquias MJ, Pinto E et. al.
Sep 7th, 2021 - Alpha-Mannosidosis: A Novel Cause of Bilateral Thalami and Dentate Nuclei Hyperintensity.|2021|Malaquias MJ,Pinto E,Oliveira J,Freixo JP,Caseiro C,|
Clinicaltrials.gov 9 results
https://clinicaltrials.gov/ct2/show/NCT03651245
Jun 13th, 2022 - Alpha-Mannosidosis is a lysosomal storage disorder of the Glycoprotein family of diseases and is closely related to Mucopolysaccharidoses.It is a rare inherited disorder that causes problems in many organs and tissues of the body. Affected individ...
https://clinicaltrials.gov/ct2/show/NCT02998879
Oct 26th, 2021 - The Primary endpoints of the study include: Safety and tolerability of velmanase alfa as per Adverse events (AEs, including IRR), vital signs, laboratory parameters (hematology, biochemistry and urinanalysis) Detection of anti-velmanase alfa antib...
https://clinicaltrials.gov/ct2/show/NCT03264040
May 13th, 2021 - Alpha-Mannosidosis is a rare lysosomal storage disorder of the Glycoprotein family of diseases and is closely related to Mucopolysaccharidoses. Alpha-Mannosidosis was first described by Dr Oekerman, from Lund in Sweden in 1967. There is another va...
https://clinicaltrials.gov/ct2/show/NCT01681953
Aug 3rd, 2020 - The overall objective of this trial is to evaluate the efficacy and safety of repeated Lamazym i.v. treatment, compared with placebo, in subjects 5-35 years of age with alpha-Mannosidosis
https://clinicaltrials.gov/ct2/show/NCT00498420
Aug 3rd, 2020 - Definition: Human alpha-mannosidosis is a rare genetic disorder, caused by the lack of lysosomal alpha-mannosidase, resulting in mental retardation, skeletal changes, hearing loss and recurrent infections. The lack of alpha-mannosidase causes a di...
News 1 results
https://www.medscape.com/viewarticle/907402
Jan 9th, 2019 - In 2018, the European Medicines Agency (EMA) recommended marketing authorization for 84 new medicines, down from 92 in 2017. The 84 medicines given a thumbs up by EMA's Committee for Medicinal Products for Human Use include 42 agents with a new ac...
